Chardan Capital Upgrades Immuneering (NASDAQ:IMRX) to “Strong-Buy”

Immuneering (NASDAQ:IMRX) was upgraded by research analysts at Chardan Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Needham & Company LLC upped their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Cantor Fitzgerald assumed coverage on Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target on the stock. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $17.57.

Immuneering Stock Performance

NASDAQ:IMRX opened at $4.39 on Monday. Immuneering has a 52 week low of $2.90 and a 52 week high of $10.08. The firm’s 50-day simple moving average is $4.60 and its 200 day simple moving average is $4.98. The firm has a market cap of $284.03 million, a price-to-earnings ratio of -3.75 and a beta of 0.43.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The company had revenue of $0.36 million during the quarter. Sell-side analysts anticipate that Immuneering will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in Immuneering in the 1st quarter valued at about $32,000. Geode Capital Management LLC increased its stake in shares of Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Immuneering in the second quarter worth about $90,000. Bridgeway Capital Management LLC raised its position in shares of Immuneering by 57.9% in the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in shares of Immuneering in the second quarter valued at approximately $215,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.